Teva Pharmaceutical Industries Ltd (TEVA.TA)
13,920.00
1 Aug 2013
-200.00₪ (-1.42%)
14,120.00₪
14,100.00₪
14,100.00₪
13,800.00₪
680,176
444,245
16,580.00₪
13,510.00₪
About
Overall
| Beta: | 0.32 |
| Market Cap (Mil.): | ₪132,843.70 |
| Shares Outstanding (Mil.): | 944.15 |
| Dividend: | 115.00 |
| Yield (%): | 3.05 |
Financials
| TEVA.TA | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 19.75 | 37.93 | 37.76 |
| EPS (TTM): | 7.12 | -- | -- |
| ROI: | -- | 19.48 | 18.76 |
| ROE: | -- | 20.17 | 19.59 |
Teva Pharm faces U.S. patent worries, dip in profits
JERUSALEM - Teva Pharmaceutical Industries profits fell in the second quarter, hurt by a decline in U.S. and European generic drug sales, and its near-term outlook looks bleak in the face of prospective competition for multiple sclerosis drug Copaxone.
CORRECTED-UPDATE 1-Teva Pharm faces U.S. patent worries, dip in profits
(Corrects 12th paragraph to show CEO said expects stronger fourth quarter, not stronger 2014)
U.S. court permits generic version of Teva MS drug a year sooner
WASHINGTON/NEW YORK - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.
UPDATE 1-US court permits generic version of Teva MS drug a year sooner
WASHINGTON/NEW YORK, July 26 - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May.
U.S. court permits generic version of Teva MS drug a year sooner
WASHINGTON, July 26 - Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court Friday.
Lonza scraps generic drug venture with Teva
ZURICH/LONDON - Specialty chemicals maker Lonza posted a bigger than expected fall in first-half profit and said it was ending a generic drugs venture with Israel's Teva Pharmaceutical Industries by mutual agreement after misjudging how much it would cost.
UPDATE 2-Lonza scraps generic drug venture with Teva
ZURICH/LONDON, July 25 - Specialty chemicals maker Lonza posted a bigger than expected fall in first-half profit and said it was ending a generic drugs venture with Israel's Teva Pharmaceutical Industries by mutual agreement after misjudging how much it would cost.
Teva and Lonza to end collaboration on biosimilars
ZURICH, July 25 - Israel-based Teva Pharmaceutical Industries and Swiss Lonza Group said they were discontining their collaboration for the development, manufacturing and marketing of biosimilars.
Teva developing new medicines to treat brain disorders -CEO
JERUSALEM, July 23 - Teva Pharmaceutical Industries expects to complete development of new medicines in the next few years aimed at treating brain disorders as the global population ages, its chief executive said.
Mylan says court dismisses some of Teva's patent claims on MS drug
- A federal court in New York ruled that Mylan Inc's generic application for a multiple sclerosis drug has not infringed some of Teva Pharmaceutical Industries' patents, Mylan said.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: MacroRisk Analytics/EconomicInvestor
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

